Monogram Orthopaedics Q1 net loss $3.5M; 510(k) submission on track for H2 2024

Monogram Technologies Inc.

2024-Q1 EPS reported -$0.11

Net loss $3.5M in Q1 2024 vs $3.9M prior year; cash $10.1M at Mar 31.
Verification & validation testing expected largely complete in Q2 2024.
FDA 510(k) submission for mBôs TKA system planned for second half of 2024.
Engaged contract research organization for OUS clinical trial activities.
R&D expenses $2.4M, up from $1.9M, driven by V&V and mVision development.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monogram Technologies Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $3.5 million.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $3.5 million
Result: reported results

Exact text from the filing

On May 14, 2024, Monogram Orthopaedics Inc., a Delaware corporation (the “Company”) issued a press release announcing, among other things, its financial results for the three months ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-060937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.